1951 NW 7TH AVENUE, MIAMI, FL
Annual Report to Security Holders
Announces 2026 First Quarter Financial Results and Provides Business Update
Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Longeveron Inc. Implements Temporary Reduction in Executive Compensation
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Other Events
Announces Closing of Private Placement of up to $30 Million
Material disclosure
Q1
FY 2025
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload